Ignyta to Report 2013 Company Highlights and Financial Results and Host Conference Call on February 28, 2014
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (OTCQB: RXDX), an oncology precision medicine biotechnology company, announced today that it will release its 2013 financial results after the market closes on Friday, February 28, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results, and answer questions.
The conference call will be available to interested parties through a live audio Internet broadcast at http://www.media-server.com/m/p/vcrg2e3z, or on the Investors page of the company’s website at http://investor.ignyta.com. The call will also be archived and accessible at both sites for one year. Alternatively, callers may participate in the conference call by dialing (888) 734-0328 (domestic) or (678) 894-3054 (international), and entering passcode 4280482.
About Ignyta, Inc.
Ignyta, Inc., located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. Our present focus is on the development of RXDX-101 and RXDX-102, our proprietary oral tyrosine kinase inhibitors that target solid tumor indications, and advancing our novel Spark discovery programs that leverage our proprietary cancer genomic and epigenomic knowledge bases. For more information, please visit: www.ignyta.com.